Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus PROMETHAZINE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus PROMETHAZINE PLAIN.
FEXOFENADINE HYDROCHLORIDE ALLERGY vs PROMETHAZINE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells and basophils.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
60 mg orally twice daily or 180 mg orally once daily.
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
None Documented
None Documented
Terminal elimination half-life is 14.4 hours in healthy adults. In renal impairment, half-life may be prolonged up to 59 hours.
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Primarily excreted unchanged in feces (80%) and urine (11%). Biliary excretion contributes to fecal elimination.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic